Drug Interaction:
Drug interactions- summary -
Drugs that alter renal function-
Because telbivudine is eliminated primarily by renal excretion, the potential for adverse
reactions is low. However, coadmin of telbivudine with drugs that alter renal function,may
alter plasma concentration of telbivudine .
Indication:
LIST OF DRUGS DURING 2006
Sr.No- 128
Name of the Drug- Telbivudine 600mg tablet Pharmacological Classification- For the treatment of hepatitis B infection
Date of Approval- 30-08-2006
Approved by U.S.FDA on 30-12-2006 (Ref- FDA approved List)
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Tebivudine 600mg tablet 30-08-2006
For Chronic Hepatitis B infection
Chronic hepatitis B
Adverse Reaction:
Adverse reactions-
CNS- fatigue 1% headache 1%
GI - abdominal pain 1% diarrhea/loose stools <1% gastritis <1%
Musculoskeletal - arthalgia <1% muscle related symptoms 2%
Respiratory - cough <1%
Miscellaneous - pyrexia 1%
Contra-Indications:
Hypersensitivity
Special precautions-
Excaberation of hepatitis- closely monitor hepatic function with both clinical and laboratory
follow-up
Renal function impairment - Dose interval and adjustments is recommended in patients with
Ccr 50mL/min including patients on dialysis .
Hepatic function impairment - monitor renal function before and during treatment with telbivudine
Pregnancy- use telbivudine during pregnancy only if needed.
Lactation- instruct mothers no to breast feed if they receiving telbivudine
Children- safety and efficacy of telbivudine in children have not been established.
Elderly- monitor renal function in elderly patients and institute dosage adjustment
accordingly
Monitoring- closely monitor hepatic functioon with both clinical and laboratory follow-up
for at least several monthsin patients who discontinue anti-heaptitis B therapy
Monitor patients for any signs of unexplained muscle pain, tenderness, or weakness.
paticularly during upward dosage titration
Dosages/ Overdosage Etc:
Indication-
Chronic hepatitis B
Dosage-
Adults and adolescents ( 16 years of age)-
600mg once daily taken with or without food
Patient Information:
1. Patients should remain under care of a doctor during treatment
2. Advice patients to promptly report any unexplained musclev weakness, tendrness
or pain.
3. Advice paients that tebivudine is not a cure for hepatitis B .
4. Inform patients that deterioration of liver disease may occur in some cases if treatment is
discontinued and that they should discuss any change in dosage regimen with their doctor
5. Inform patients that treatment with telbivudine has not been to reduce the risk of transmission
of HBV to others through sexual contact.
Interaction with Food:
Can be taken with or without food.
Pregnancy and lactation:
Pregnancy-
Use telbivudine during pregnancy only if needed.
Lactation-
Instruct mothers no to breast feed if they receiving telbivudine
Children-
Safety and efficacy of telbivudine in children have not been established.
Elderly-
Monitor renal function in elderly patients and institute dosage adjustment
accordingly